Гастроэзофагеальная рефлюксная болезнь и эзофагит, ассоциированные с применением лекарственных препаратов: современное состояние проблемы
________________________________________________
Osadchuk A.M., Davydkin I.L., Gricenko T.А., Osadchuk M.A. Gastroesophageal reflux disease and esophagitis associated with the use of drugs: the modern state of the problem. Therapeutic Archive. 2019; 91 (8): 135–140. DOI: 10.26442/00403660.2019.08.000228
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: медикаментозный рефлюкс-эзофагит, цитостатики, глюкокортикостероиды, нестероидные противовоспалительные средства, антидепрессанты, контрацептивные препараты.
________________________________________________
From the standpoint of evidence-based medicine, the ability of various drugs to induce the development of gastroesophageal reflux disease and esophagitis is considered. Thus, all known drugs can be divided into 3 groups: drugs that have the ability to reduce pressure in the lower esophageal sphincter, for example, β-adrenoreceptor agonists, α-adrenoreceptor antagonists, anticholinergics, calcium channel blockers, nitrates, benzodiazepines (diazepam), estrogen, progesterone, aminophylline (theophylline), tricyclic antidepressants, selective serotonin reuptake inhibitors, glucocorticosteroids; means providing a direct damaging effect on the esophageal mucosa, as well as lowering its resistance reflyuktatu, e.g., bisphosphonates, acetylsalicylic acid / non-steroidal anti-inflammatory agents, anticoagulants, antiplatelet drugs, iron preparations, ascorbic acid, potassium chloride, quinidine, phenytoin, calcium dobesilate, 131I sodium iodide, antibiotics (tetracycline, doxycycline, clindamycin, ciprofloxacin, ornidazole, clindamycin, rifampicin), antitumor agents; drugs that impede gastric emptying: calcium channel blockers, anticholinergics. These data can be used in practice in the choice of treatment tactics, especially in individuals with a diagnosis of gastroesophageal reflux disease or heartburn.
Keywords: medical reflux esophagitis, cytostatics, glucocorticosteroids, nonsteroidal anti-inflammatory drugs, antidepressants, contraceptive drugs.
2. Zografos GN, Georgiadou D, Thomas D, Kaltsas G, Digalakis M. Drug-induced esophagitis. Dis Esophagus. 2009;22(8):633-7. doi: 10.1111/j.1442-2050.2009.00972.x
3. Пахомова И.Г., Хорошинина Л.П. НПВП-индуцированная эзофагопатия: просто ГЭРБ или еще одна нозологическая единица? Фарматека. 2016;15(328):39-43 [Pakhomova IG, Khoroshinina LP. NSAID-induced esophagopathy: just gerd or another disease entity? Farmateka. 2016;15(328):39-43 (In Russ.)].
4. Pandeya N, Green AC, Whiteman DC. Australian Cancer Study. Prevalence and determinants of frequent gastroesophageal reflux symptoms in the Australian community. Dis Esophagus. 2012;25:573-83. doi: 10.1111/j.1442-2050.2011.01287.x
5. Nasseri-Moghaddam S, Mofid A, Ghotbi MH, Razjouyan H, Nouraie M, Ramard AR, Zaer-Rezaie H, Habibi R, Rafat-Zand K, Malekzadeh R. Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther. 2008;28:144-53. doi: 10.1111/j.1365-2036.2008.03708.x
6. Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001;18:1367-72.
7. Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004;20:751-60.
8. Scheiman JM, Patel PM, Henson EK, Nostrant TT. Effect of naproxen on gastroesophageal reflux and esophageal function: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 1995;90:754-7.
9. Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA. Impact of compliance with proton pump inhibitors on NSAID treatment. Am J Manag Care. 2009;15:681-8.
10. Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther. 2008;28:1134-9. doi: 10.1111/j.1365-2036.2008.03821.x
11. Martín-de-Argila C, Martínez-Jiménez P. Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs. Expert Rev Gastroenterol Hepatol. 2013;7:27-33. doi: 10.1586/egh.12.61
12. Sugisaki N, Iwakiri R, Tsuruoka N, Sakata Y, Shimoda R, Fujimoto S, Eguchi Y, Fujimoto K. A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients. J Gastroenterol. 2018 Jun 12. doi: 10.1007/s00535-018-1483-x
13. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47.
14. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking lowdose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:119-25.
15. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018 Mar;67(3):430-40. doi: 10.1136/gutjnl-2016-313589
16. Zheng Z, Margolis KL, Liu S, Tinker LF, Ye W. Women's Health Initiative Investigators. Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. Gastroenterology. 2008;135:72-81. doi: 10.1053/j.gastro.2008.03.039
17. Close H., Mason JM, Wilson D, Hungin AP. Hormone replacement therapy is associated with gastro-oesophageal reflux disease: a retrospective cohort study. BMC Gastroenterol. 2012 May 29;12:56. doi: 10.1186/1471-230X-12-56
18. Nordenstedt H, Zheng Z, Cameron AJ, Ye W, Pedersen NL, Lagergren J. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology. 2008 Apr;134(4):921-8. doi: 10.1053/j.gastro.2008.01.009
19. Jacobson BC, Moy B, Colditz GA, Fuchs CS. Postmenopausal hormone use and symptoms of gastroesophageal reflux. Arch Intern Med. 2008 Sep 8;168(16):1798-804. doi: 10.1001/archinte.168.16.1798
20. Araujo AC, Lobo N, Barbosa S, Bandeira E, Bandeir F. Chronic Oral Alendronate Use is Associated with Gastrointestinal Reflux Disease and Voice Alterations Irrespective of the Presence of Esophagitis. Brit J Medicin Med Res. 2017;19(12):1-7. doi: 10.9734/BJMMR/2017/31790
21. Ang C, Doyle E, Branch A. Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World J Gastroenterol. 2016 Jan 21;22(3):906-16. doi: 10.3748/wjg.v22.i3.906
22. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 1998;4:1377-82.
23. Lin D, Kramer JR, Ramsey D, Alsarraj A, Verstovsek G, Rugge M, Parente P, Graham DY, El-Serag HB. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol. 2013 Oct;108(10):1576-83. doi: 10.1038/ajg.2013.222
24. Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M. High incidence of newly-developed gastroesophageal reflux disease in the Japanese community: a 6-year follow-up study. J Gastroenterol Hepatol. 2008 Mar;23(3):393-7.
25. Nakaji G, Fujihara M, Fukata M, Yasuda S, Odashiro K, Maruyama T, Akashi K. Influence of common cardiac drugs on gastroesophageal reflux disease: multicenter questionnaire survey. Int J Clin Pharmacol Ther. 2011;49:555-62.
26. Hughes J, Lockhart J, Joyce A. Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain? Br J Clin Pharmacol. 2007;64:83-9. doi: 10.1111/j.1365-2125.2007.02851.x
27. Stacher G, Schneider C, Steinringer H, Holzäpfel A, Gaupmann G, Stacher-Janotta G. Effects of 3-days' intake of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate, on oesophageal motility. Aliment Pharmacol Ther. 1997 Oct;11(5):967-71.
28. Nasseri-Moghaddam S, Mofid A, Razjouyan H. Dietary nitrate may have a role in development of gastro-esophageal reflux disease. Arch Iran Med. 2011 Sep; 14(5):312-4.
29. Savarino E, Zentilin P, Marabotto E, Bodini G, Della Coletta M, Frazzoni M, de Bortoli N, Martinucci I, Tolone S, Pellegatta G, Savarino V. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2017 Sep;18(13):1333-43. doi: 10.1080/14656566.2017.1361407
30. Martín-Merino E, Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S. Depression and treatment with antidepressants are associated with the development of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2010;31:1132-40.
31. Van Soest EM, Dieleman JP, Siersema PD, Schoof L, Sturkenboom MC, Kuipers EJ. Tricyclic antidepressants and the risk of reflux esophagitis. Am J Gastroenterol. 2007;102:1870-7.
32. Rushnak MJ, Leevy CM. Effect of diazepam on the lower esophageal sphincter. A double-blind controlled study. Am J Gastroenterol. 1980;73:127-32.
33. Singh S, Bailey RT, Stein HJ, De Meester TR, Richter JE. Effect of alprazolam (Xanax) on esophageal motility and acid reflux. Am J Gastroenterol. 1992;87:483-8.
34. Gagliardi GS, Shah AP, Goldstein M, Denua-Rivera S, Doghramji K, Cohen S, Dimarino AJ Jr. Effect of zolpidem on the sleep arousal response to nocturalesophageal acid exposure. Clin Gastroenterol Hepatol. 2009 Sep;7(9):948-52. doi: 10.1016/j.cgh.2009.04.026
35. Koerselman J, Pursnani KG, Peghini P, Mohiuddin MA, Katzka D, Akkermans LM, Castell DO. Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: a pilot study. Am J Gastroenterol. 1999;94:925-30.
36. Ciccaglione AF, Grossi L, Cappello G, Malatesta MG, Ferri A, Toracchio S, Marzio L. Effect of hyoscine Nbutylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:2306-11.
37. Mosli M, Alkhathlan B, Abumohssin A, Merdad M, Alherabi A, Marglani O, Jawa H, Alkhatib T, Marzouki HZ. Prevalence and clinical predictors of LPR among patients diagnosed with GERD according to the reflux symptom index questionnaire. Saudi J Gastroenterol. 2018 Jul-Aug;24(4):236-41. doi: 10.4103/sjg.SJG_518_17
38. Maio S, Baldacci S, Bresciani M, Simoni M, Latorre M, Murgia N, et al. RItA: The Italian severe/uncontrolled asthma registry. Allergy. 2018 Mar;73(3):683-95. doi: 10.1111/all.13342
39. Mungan Z, Şimşek BP. Which drugs are risk factors for the development of gastroesophageal reflux disease. Turk J Gastroenterol. 2017;28(Suppl 1):S38-S43. doi: 10.5152/tjg.2017.11
40. Crowell MD, Zayat EN, Lacy BE, Schettler-Duncan A, Liu MC. The effects of an inhaled beta(2)-adrenergic agonist on lower esophageal function: a dose-response study. Chest. 2001;120(4):1184-9.
41. Kim SW, Lee JH, Sim YS, Ryu YJ, Chang JH. Prevalence and risk factors for reflux esophagitis in patients with chronic obstructive pulmonary disease. Korean J Intern Med. 2014;29:466-73. doi: 10.3904/kjim.2014.29.4.466
42. Grossi L, Ciccaglione AF, Marzio L. Esophagitis and its causes: Who is “guilty” when acid is found “not guilty”? World J Gastroenterol. 2017 May 7;23(17):3011-6. doi: 10.3748/wjg.v23.i17.3011
43. Uwagawa T, Misawa T, Iida T, Sakamoto T, Gocho T, Wakiyama S, Hirohara S, Yanaga K. Proton-Pump Inhibitor as Palliative Care for Chemotherapy-Induced Gastroesophageal Reflux Disease in Pancreatic Cancer Patients. J Palliat Med. 2010 Jul;13(7):815-8. doi: 10.1089/jpm.2009.0404
44. Dahms BB, Greco MA, Strandjord SE, Rothstein FC. Barrett's esophagus in three children after antileukemia chemotherapy. Cancer. 1987 Dec 15;60(12):2896-900.
45. Peters FT, Sleijfer DT, van Imhoff GW, Kleibeuker JH. Is chemotherapy associated with development of Barrett's esophagus? Dig Dis Sci. 1993 May;38(5):923-6.
46. Schiavetti A, Di Nardo G, Ingrosso A, Chiriacò D, Cucchiara S. Barrett esophagus in long-term survivors of childhood solid tumors. J Pediatr Hematol Oncol. 2011 Oct;33(7):559-61. doi: 10.1097/MPH.0b013e318217237b
47. Garipardic M, Bakan V, Davutoğlu M, Sayar H, Kurutaş EB. Oxidative stress and protective effect of erythropoietin on methotrexate-induced esophageal damage. J Pediatr Hematol Oncol. 2010 Mar;32(2):108-12. doi: 10.1097/MPH.0b013e3181ccb678
48. Biacabe B, Gleich LL, Laccourreye O, Hartl DM, Bouchoucha M, Brasnu D. Silent gastroesophageal reflux disease in patients with pharyngolaryngeal cancer: further results. Head Neck. 1998 Sep;20(6):510-4.
49. Asai S, Nagai K, Takahashi N, Watanabe T, Matsumoto T, Asai N, Sobue Y, Ishiguro N, Kojima T. Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis. Int J Rheum Dis. 2018 Aug 30. doi: 10/1111/1756-185Х.13380
50. Давыдкин И.Л., Осадчук А.М., Гриценко Т.А., Куртов И.В. Рефрактерная форма гастроэзофагеальной рефлюксной болезни: эволюция представлений. Наука и инновации в медицине. 2017;1(5):24-30 [Davydkin IL, Osadchuk AM, Gritsenko TA, Kurtov IV. Refractory form of gastroesophageal reflux disease: evolution of concepts. Nauka i Innovacii v Medicine. 2017;1(5):24-30 (In Russ.)].
51. Nampei A, Shi K, Ebina K, Tomita T, Sugamoto K, Yoshikawa H, Hirao M, Hashimoto J. Prevalence of gastroesophageal reflux disease symptoms and related factors in patients with rheumatoid arthritis. J Clin Biochem Nutr. 2013 Mar;52(2):179-84. doi: 10.3164/jcbn.12-83
52. Lazenby JP, Guzzo MR, Harding SM, Patterson PE, Johnson LF, Bradley LA. Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest. 2002 Feb;121(2):625-34.
53. Sørensen HT, Mellemkjaer L, Friis S, Olsen JH. Use of Systemic Corticosteroids and Risk of Esophageal Cancer. Epidemiology. 2002 Mar;13(2):240-1.
54. Turan A, Wo J, Kasuya Y, Govinda R, Akça O, Dalton JE, Sessler DI, Rauch S. Effects of dexmedetomidine and propofol on lower esophageal sphincter and gastroesophagealpressure gradient in healthy volunteers. Anesthesiology. 2010 Jan; 112(1):19-24. doi: 10.1097/01.anes.0000365963.97138.54
________________________________________________
1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871-80. doi: 10.1136/gutjnl-2012-304269
2. Zografos GN, Georgiadou D, Thomas D, Kaltsas G, Digalakis M. Drug-induced esophagitis. Dis Esophagus. 2009;22(8):633-7. doi: 10.1111/j.1442-2050.2009.00972.x
3. [Pakhomova IG, Khoroshinina LP. NSAID-induced esophagopathy: just gerd or another disease entity? Farmateka. 2016;15(328):39-43 (In Russ.)].
4. Pandeya N, Green AC, Whiteman DC. Australian Cancer Study. Prevalence and determinants of frequent gastroesophageal reflux symptoms in the Australian community. Dis Esophagus. 2012;25:573-83. doi: 10.1111/j.1442-2050.2011.01287.x
5. Nasseri-Moghaddam S, Mofid A, Ghotbi MH, Razjouyan H, Nouraie M, Ramard AR, Zaer-Rezaie H, Habibi R, Rafat-Zand K, Malekzadeh R. Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther. 2008;28:144-53. doi: 10.1111/j.1365-2036.2008.03708.x
6. Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001;18:1367-72.
7. Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004;20:751-60.
8. Scheiman JM, Patel PM, Henson EK, Nostrant TT. Effect of naproxen on gastroesophageal reflux and esophageal function: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 1995;90:754-7.
9. Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA. Impact of compliance with proton pump inhibitors on NSAID treatment. Am J Manag Care. 2009;15:681-8.
10. Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther. 2008;28:1134-9. doi: 10.1111/j.1365-2036.2008.03821.x
11. Martín-de-Argila C, Martínez-Jiménez P. Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs. Expert Rev Gastroenterol Hepatol. 2013;7:27-33. doi: 10.1586/egh.12.61
12. Sugisaki N, Iwakiri R, Tsuruoka N, Sakata Y, Shimoda R, Fujimoto S, Eguchi Y, Fujimoto K. A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients. J Gastroenterol. 2018 Jun 12. doi: 10.1007/s00535-018-1483-x
13. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47.
14. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking lowdose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:119-25.
15. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018 Mar;67(3):430-40. doi: 10.1136/gutjnl-2016-313589
16. Zheng Z, Margolis KL, Liu S, Tinker LF, Ye W. Women's Health Initiative Investigators. Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. Gastroenterology. 2008;135:72-81. doi: 10.1053/j.gastro.2008.03.039
17. Close H., Mason JM, Wilson D, Hungin AP. Hormone replacement therapy is associated with gastro-oesophageal reflux disease: a retrospective cohort study. BMC Gastroenterol. 2012 May 29;12:56. doi: 10.1186/1471-230X-12-56
18. Nordenstedt H, Zheng Z, Cameron AJ, Ye W, Pedersen NL, Lagergren J. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology. 2008 Apr;134(4):921-8. doi: 10.1053/j.gastro.2008.01.009
19. Jacobson BC, Moy B, Colditz GA, Fuchs CS. Postmenopausal hormone use and symptoms of gastroesophageal reflux. Arch Intern Med. 2008 Sep 8;168(16):1798-804. doi: 10.1001/archinte.168.16.1798
20. Araujo AC, Lobo N, Barbosa S, Bandeira E, Bandeir F. Chronic Oral Alendronate Use is Associated with Gastrointestinal Reflux Disease and Voice Alterations Irrespective of the Presence of Esophagitis. Brit J Medicin Med Res. 2017;19(12):1-7. doi: 10.9734/BJMMR/2017/31790
21. Ang C, Doyle E, Branch A. Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World J Gastroenterol. 2016 Jan 21;22(3):906-16. doi: 10.3748/wjg.v22.i3.906
22. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 1998;4:1377-82.
23. Lin D, Kramer JR, Ramsey D, Alsarraj A, Verstovsek G, Rugge M, Parente P, Graham DY, El-Serag HB. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol. 2013 Oct;108(10):1576-83. doi: 10.1038/ajg.2013.222
24. Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M. High incidence of newly-developed gastroesophageal reflux disease in the Japanese community: a 6-year follow-up study. J Gastroenterol Hepatol. 2008 Mar;23(3):393-7.
25. Nakaji G, Fujihara M, Fukata M, Yasuda S, Odashiro K, Maruyama T, Akashi K. Influence of common cardiac drugs on gastroesophageal reflux disease: multicenter questionnaire survey. Int J Clin Pharmacol Ther. 2011;49:555-62.
26. Hughes J, Lockhart J, Joyce A. Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain? Br J Clin Pharmacol. 2007;64:83-9. doi: 10.1111/j.1365-2125.2007.02851.x
27. Stacher G, Schneider C, Steinringer H, Holzäpfel A, Gaupmann G, Stacher-Janotta G. Effects of 3-days' intake of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate, on oesophageal motility. Aliment Pharmacol Ther. 1997 Oct;11(5):967-71.
28. Nasseri-Moghaddam S, Mofid A, Razjouyan H. Dietary nitrate may have a role in development of gastro-esophageal reflux disease. Arch Iran Med. 2011 Sep; 14(5):312-4.
29. Savarino E, Zentilin P, Marabotto E, Bodini G, Della Coletta M, Frazzoni M, de Bortoli N, Martinucci I, Tolone S, Pellegatta G, Savarino V. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2017 Sep;18(13):1333-43. doi: 10.1080/14656566.2017.1361407
30. Martín-Merino E, Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S. Depression and treatment with antidepressants are associated with the development of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2010;31:1132-40.
31. Van Soest EM, Dieleman JP, Siersema PD, Schoof L, Sturkenboom MC, Kuipers EJ. Tricyclic antidepressants and the risk of reflux esophagitis. Am J Gastroenterol. 2007;102:1870-7.
32. Rushnak MJ, Leevy CM. Effect of diazepam on the lower esophageal sphincter. A double-blind controlled study. Am J Gastroenterol. 1980;73:127-32.
33. Singh S, Bailey RT, Stein HJ, De Meester TR, Richter JE. Effect of alprazolam (Xanax) on esophageal motility and acid reflux. Am J Gastroenterol. 1992;87:483-8.
34. Gagliardi GS, Shah AP, Goldstein M, Denua-Rivera S, Doghramji K, Cohen S, Dimarino AJ Jr. Effect of zolpidem on the sleep arousal response to nocturalesophageal acid exposure. Clin Gastroenterol Hepatol. 2009 Sep;7(9):948-52. doi: 10.1016/j.cgh.2009.04.026
35. Koerselman J, Pursnani KG, Peghini P, Mohiuddin MA, Katzka D, Akkermans LM, Castell DO. Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: a pilot study. Am J Gastroenterol. 1999;94:925-30.
36. Ciccaglione AF, Grossi L, Cappello G, Malatesta MG, Ferri A, Toracchio S, Marzio L. Effect of hyoscine Nbutylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:2306-11.
37. Mosli M, Alkhathlan B, Abumohssin A, Merdad M, Alherabi A, Marglani O, Jawa H, Alkhatib T, Marzouki HZ. Prevalence and clinical predictors of LPR among patients diagnosed with GERD according to the reflux symptom index questionnaire. Saudi J Gastroenterol. 2018 Jul-Aug;24(4):236-41. doi: 10.4103/sjg.SJG_518_17
38. Maio S, Baldacci S, Bresciani M, Simoni M, Latorre M, Murgia N, et al. RItA: The Italian severe/uncontrolled asthma registry. Allergy. 2018 Mar;73(3):683-95. doi: 10.1111/all.13342
39. Mungan Z, Şimşek BP. Which drugs are risk factors for the development of gastroesophageal reflux disease. Turk J Gastroenterol. 2017;28(Suppl 1):S38-S43. doi: 10.5152/tjg.2017.11
40. Crowell MD, Zayat EN, Lacy BE, Schettler-Duncan A, Liu MC. The effects of an inhaled beta(2)-adrenergic agonist on lower esophageal function: a dose-response study. Chest. 2001;120(4):1184-9.
41. Kim SW, Lee JH, Sim YS, Ryu YJ, Chang JH. Prevalence and risk factors for reflux esophagitis in patients with chronic obstructive pulmonary disease. Korean J Intern Med. 2014;29:466-73. doi: 10.3904/kjim.2014.29.4.466
42. Grossi L, Ciccaglione AF, Marzio L. Esophagitis and its causes: Who is “guilty” when acid is found “not guilty”? World J Gastroenterol. 2017 May 7;23(17):3011-6. doi: 10.3748/wjg.v23.i17.3011
43. Uwagawa T, Misawa T, Iida T, Sakamoto T, Gocho T, Wakiyama S, Hirohara S, Yanaga K. Proton-Pump Inhibitor as Palliative Care for Chemotherapy-Induced Gastroesophageal Reflux Disease in Pancreatic Cancer Patients. J Palliat Med. 2010 Jul;13(7):815-8. doi: 10.1089/jpm.2009.0404
44. Dahms BB, Greco MA, Strandjord SE, Rothstein FC. Barrett's esophagus in three children after antileukemia chemotherapy. Cancer. 1987 Dec 15;60(12):2896-900.
45. Peters FT, Sleijfer DT, van Imhoff GW, Kleibeuker JH. Is chemotherapy associated with development of Barrett's esophagus? Dig Dis Sci. 1993 May;38(5):923-6.
46. Schiavetti A, Di Nardo G, Ingrosso A, Chiriacò D, Cucchiara S. Barrett esophagus in long-term survivors of childhood solid tumors. J Pediatr Hematol Oncol. 2011 Oct;33(7):559-61. doi: 10.1097/MPH.0b013e318217237b
47. Garipardic M, Bakan V, Davutoğlu M, Sayar H, Kurutaş EB. Oxidative stress and protective effect of erythropoietin on methotrexate-induced esophageal damage. J Pediatr Hematol Oncol. 2010 Mar;32(2):108-12. doi: 10.1097/MPH.0b013e3181ccb678
48. Biacabe B, Gleich LL, Laccourreye O, Hartl DM, Bouchoucha M, Brasnu D. Silent gastroesophageal reflux disease in patients with pharyngolaryngeal cancer: further results. Head Neck. 1998 Sep;20(6):510-4.
49. Asai S, Nagai K, Takahashi N, Watanabe T, Matsumoto T, Asai N, Sobue Y, Ishiguro N, Kojima T. Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis. Int J Rheum Dis. 2018 Aug 30. doi: 10/1111/1756-185Х.13380
50. [Davydkin IL, Osadchuk AM, Gritsenko TA, Kurtov IV. Refractory form of gastroesophageal reflux disease: evolution of concepts. Nauka i Innovacii v Medicine. 2017;1(5):24-30 (In Russ.)].
51. Nampei A, Shi K, Ebina K, Tomita T, Sugamoto K, Yoshikawa H, Hirao M, Hashimoto J. Prevalence of gastroesophageal reflux disease symptoms and related factors in patients with rheumatoid arthritis. J Clin Biochem Nutr. 2013 Mar;52(2):179-84. doi: 10.3164/jcbn.12-83
52. Lazenby JP, Guzzo MR, Harding SM, Patterson PE, Johnson LF, Bradley LA. Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest. 2002 Feb;121(2):625-34.
53. Sørensen HT, Mellemkjaer L, Friis S, Olsen JH. Use of Systemic Corticosteroids and Risk of Esophageal Cancer. Epidemiology. 2002 Mar;13(2):240-1.
54. Turan A, Wo J, Kasuya Y, Govinda R, Akça O, Dalton JE, Sessler DI, Rauch S. Effects of dexmedetomidine and propofol on lower esophageal sphincter and gastroesophagealpressure gradient in healthy volunteers. Anesthesiology. 2010 Jan; 112(1):19-24. doi: 10.1097/01.anes.0000365963.97138.54
1 ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, Самара, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
________________________________________________
A.M. Osadchuk 1, I.L. Davydkin 1, T.А. Gricenko 1, M.A. Osadchuk 2
1 Samara State Medical University, Samara, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia